Osiris Therapeutics entered into an exclusive, worldwide partnership with Stryker for the commercialization and development of its viable bone matrix tissue form.
Here are three things to know about the partnership:
1. The partnership strategically aligns one of Osiris' leading regenerative medicine technologies with Stryker's medical device portfolio.
2. Originally branded as OvationOS, Osiris' viable bone matrix tissue form will now be marketed by Stryker under the brand name BIO4. Osiris will be responsible for manufacturing, continued research and product improvement activities while Stryker will be responsible for the commercialization and marketing of BIO4.
3. BIO4 is a bone allograft that contains both viable cells and growth factors. It provides an alternative to autografts that minimizes the potential for harvest site co-morbidities.
More articles on devices:
Journey to market: Orthopedic trauma surgeons map out 5 steps for their new device
Upstate University Hospital implements MAKOplasty technology
10 trends in the global powered surgical instruments market